Invention Grant
- Patent Title: Macrocyclic compounds as HCV entry inhibitors
-
Application No.: US14765910Application Date: 2014-02-04
-
Publication No.: US09624245B2Publication Date: 2017-04-18
- Inventor: Tao Wang , Zhongxing Zhang , Zhiwei Yin , Li-Qiang Sun , Eric Mull , Qian Zhao , Paul Michael Scola
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent John F. Levis
- International Application: PCT/US2014/014654 WO 20140204
- International Announcement: WO2014/123894 WO 20140814
- Main IPC: C07D519/00
- IPC: C07D519/00 ; C07D498/22 ; C07D498/08 ; C07D498/18 ; A61K31/53 ; A61K31/551 ; A61K45/06 ; C07D498/20

Abstract:
Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
Public/Granted literature
- US20150368267A1 MACROCYCLIC COMPOUNDS AS HCV ENTRY INHIBITORS Public/Granted day:2015-12-24
Information query